Clinical TrialJun 4, 2026, 01:01 AM
Biogen & UCB Present Positive Phase 3 SLE Data at EULAR 2026
AI Summary
UCB and Biogen Inc. announced positive data from the Phase 3 PHOENYCS GO study for dapirolizumab pegol (DZP) in systemic lupus erythematosus (SLE) at the EULAR 2026 Congress. The results showed that DZP, combined with standard of care, was associated with sustained disease control at lower glucocorticoid doses through Week 48, supporting reduced long-term steroid exposure. Additionally, improvements in immunological markers and reduced flare rates were observed, highlighting DZP's potential to address the complex burden of SLE.
Key Highlights
- Dapirolizumab pegol (DZP) plus standard of care was associated with sustained disease control at lower glucocorticoid doses through Week 48.
- Higher proportion of patients on DZP achieved disease control while tapering steroids to 7.5 mg/day through Week 48.
- Improvements in immunological markers, including reduced anti-dsDNA antibodies and increased complement proteins C3 and C4, were observed.
- Lower rates of moderate or moderate/severe BILAG-2004 flares were seen with DZP plus standard of care.
- The Phase 3 PHOENYCS GO study demonstrated a generally favorable safety profile for DZP.
- Serious treatment-emergent adverse events were less frequent in the DZP plus standard of care arm.
Price Impact
More from BIIB